Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768536 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10319583 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1759405 | 1.00 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL10670770 | 0.98 | DRD4 (0.69) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8325714 | 0.91 | DRD4 (0.60) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7368320 | 0.91 | DRD4 (0.59) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7262675 | 0.88 | DRD4 (0.76) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4228489 | 0.86 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8327024 | 0.86 | DRD4 (0.65) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4029420 | 0.86 | DRD4 (0.62) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | claimed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117434198-A | Method for detecting 2-aminomethyl-4-benzyl morpholine in 2-aminomethyl-4- (4-fluorobenzyl) morpholine | 黑龙江珍宝岛药业股份有限公司鸡西分公司 | 2024-01-23 | — | — | CN | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-4889857-A | BACTERICIDES; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0311948-A2 | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| US-4748175-A | Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions containing them | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1988-05-31 | — | — | US | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| CN-86108914-A | Process for preparing pyrimido [5, 4-b ] [1, 4] oxazine derivatives and pharmaceutical agents containing the same | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1987-09-30 | — | — | CN | disclosed |
| EP-0228094-A2 | Pyrimido[5,4-b][1,4]oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido[5,4-b][1,4]oxazine derivatives | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | DRD4 1998/4885CYP1A2 568/4885CYP3A4 2014/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | DRD4 2045/4885CYP1A2 2151/4885CYP3A4 2898/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | DRD4 2045/4885CYP1A2 2151/4885CYP3A4 2898/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | DRD4 3676/4885CYP1A2 1572/4885CYP3A4 3301/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | DRD4 2045/4885CYP1A2 2151/4885CYP3A4 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.